GSK plc
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Luke Victor Miels
- Full Time Employees
- 66,841
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- 79 New Oxford Street London GL United Kingdom WC1A 1DG
- IPO Date
- Mar 28, 1980
- CIK
- 0001131399
- Website
- gsk.com
- Similar Companies
- Business
- GSK plc is a British multinational biopharmaceutical company that discovers, develops, manufactures and markets prescription medicines, vaccines and specialty therapies focused on respiratory/immunology, oncology, HIV and infectious diseases. Founded through the 2000 merger of Glaxo Wellcome and SmithKline Beecham with origins tracing to 1715, the company is headquartered at 79 New Oxford Street in London, England, and operates globally with manufacturing sites in 37 countries, delivering products to markets including the US, Europe, Asia and emerging regions. Its core portfolio encompasses specialty medicines such as Nucala (mepolizumab) for severe eosinophilic asthma, COPD and CRSwNP; Jemperli (dostarlimab) for endometrial cancer; Blenrep (belantamab mafodotin) for multiple myeloma; Arexvy and Shingrix vaccines for RSV and shingles respectively; a broad range of over 20 vaccines targeting meningococcal disease (e.g. Penmenvy, a 5-in-1 MenABCWY vaccine), HPV, hepatitis and influenza; HIV treatments via ViiV Healthcare including long-acting injectables like Cabenuva (cabotegravir + rilpivirine), Apretude for PrEP and investigational assets like N6LS; general medicines including inhalers for asthma/COPD, antibiotics and gepotidacin (Blujepa) for UTIs; and oncology offerings like Zejula (niraparib) for ovarian cancer. In recent developments, GSK completed the $1.15 billion acquisition of IDRx Inc. in 2025 to advance IDRX-42, a next-generation KIT inhibitor for GIST adding to its GI cancer portfolio; entered a potential $12 billion alliance with Hengrui Pharma paying $500 million upfront for rights to a COPD candidate and up to 11 respiratory, immunology and oncology programs outside greater China; acquired exclusive rights from Syndivia for a prostate cancer antibody-drug conjugate; launched or gained approvals for five new products/line extensions in 2025 including Penmenvy, Blujepa, Nucala for COPD and depemokimab (under FDA/EMA review as the first 6-month ultra-long-acting biologic for type 2 asthma and CRSwNP); announced a $30 billion US investment over five years including a $1.2 billion biologics facility in Pennsylvania; established the GSK-Oxford Cancer Immuno-Prevention Programme; and relocated its headquarters to central London while preparing for CEO transition to Luke Miels in 2026.
Trump wants to split the MMR vaccine. Experts say that's unlikely — and comes with consequences
GSK India first-quarter profit rises on steady vaccine demand
GSK, Relation Therapeutics sign up to $110 million AI drug discovery deal
GSK Beats Q2 Earnings & Revenue Estimates, Announces Cost-Saving Plan
GSK plc (GSK) Q2 2026 Earnings Call Transcript
GSK Q2 Earnings Call Highlights
GSK: Healthy Results, But Limited Stock Upside (Rating Downgrade)
GSK hits three-month high as vaccines help earnings top forecasts
GSK hits three-month high as vaccines help earnings top forecasts
GSK (GSK) Beats Q2 Earnings and Revenue Estimates
GSK Launches Cost-Saving Plan to Accelerate Drug Pipeline
GSK beats second-quarter profit estimates, launches $2.52 billion cost savings drive
GSK to invest £400 million in Britain over 3 years as it ramps up R&D efforts
GSK, Hansoh's cancer drug meets main goal of bone cancer trial
Bank of New York Mellon Corp Reduces Holdings in GSK PLC Sponsored ADR $GSK
FTSE 100 shares to watch: Lloyds, Barclays, IAG, NatWest, GSK, AstraZeneca
SMMT Shares Updated Ivonescimab Survival Data From NSCLC Study
GSK Lands FDA Approval for Nuvalent-Acquired Jideytro for NSCLC
Will GSK's Specialty Medicines Boost Q2 Revenue Growth?
Jideytro (zidesamtinib) approved in the US for previously treated ROS1-positive non-small cell lung cancer